Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Kisspeptin-54 cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established Kisspeptin-54 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Human studies ranged from single-session infusions to 2 weeks of repeated administration 1,3.
  2. Follicular-phase exposure over 1 week in healthy women 4.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Kisspeptin-54 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Kisspeptin-54 cycle length?
No. Human studies administered Kisspeptin-54 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Kisspeptin-54?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Kisspeptin-54 dosing reference Full research page

References

  1. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males J Clin Endocrinol Metab. 2005
  2. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women J Clin Endocrinol Metab. 2007
  3. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis J Clin Endocrinol Metab. 2009
  4. Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers J Clin Endocrinol Metab. 2013
  5. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization J Clin Invest. 2014
  6. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy J Clin Endocrinol Metab. 2015
  7. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial Hum Reprod. 2017
  8. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans EBioMedicine. 2025
  9. Drugs@FDA application data queried through openFDA for kisspeptin (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  10. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
  11. PubChem compound record for kisspeptin (kisspeptin-54, metastin) (CID 71306396; CAS 388138-21-4) PubChem. 2026
  12. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026